

**Calgary Zone LTC Formulary Highlights: Feb 5, 2024**

[Calgary Zone LTC Formulary Highlights \(albertahealthservices.ca\)](https://albertahealthservices.ca)

**By: Calgary Zone LTC Pharmacy & Therapeutics Committee**

**Contents**

February 2024..... 3

**Formulary Changes (Additions, Changes, Deletions)..... 3**

**Other Formulary Updates ..... 3**

December 2023..... 3

**Formulary Changes (Additions, Changes, Deletions)..... 3**

**Other Formulary Updates ..... 4**

September 2023 ..... 4

**Formulary Changes (Additions, Changes, Deletions)..... 5**

**Other Formulary Updates ..... 6**

June 30, 2023 ..... 7

**Formulary Changes (Additions, Changes, Deletions)..... 7**

**Other Formulary Updates ..... 7**

April 30, 2023..... 8

**Formulary Changes (Additions, Changes, Deletions)..... 8**

**Other Formulary Updates ..... 9**

February 2024

**Formulary Changes (Additions, Changes, Deletions)**

The following drug product(s) listing changes to the Calgary Zone Long Term Care Formulary are complete. When available, consider the lowest cost alternative (LCA) product the benefit.

<b>Product Description</b>	<b>Strength (Dosage Form)</b>	<b>Route of Administration</b>	<b>Listing / Comments</b>
glucagon nasal powder (Baqsimi)	3 mg device	intranasal	Added to Formulary with restrictions (RS-11)
glucagon kit (Amphastar)	1mg/vial	injection	Temporary listing with restrictions (RS-11) until July 1, 2024

**Other Formulary Updates**

- **Formulary Policies and Procedures**
  - [Wardstock/Statbox Lists](#)
    - the glucagon listings were updated.
- **Formulary Medication Listing**
  - The [Full Formulary Listing](#) was updated to reflect the changes in the above table.
- **Restricted Use Medications**
  - The [Restricted Use Medications – Miscellaneous Drugs](#) (RS-11) table was updated to reflect the changes to glucagon.

December 2023

**Formulary Changes (Additions, Changes, Deletions)**

The following drug product(s) listing changes to the Calgary Zone Long Term Care Formulary are complete. When available, consider the lowest cost alternative (LCA) product the benefit.

<b>Product Description</b>	<b>Strength (Dosage Form)</b>	<b>Route of Administration</b>	<b>Listing / Comments</b>
salicylic acid	17% to 40% (gel or solution)	topical	Added to Formulary (open listing). Select the lowest cost option with availability.

carboxymethylcellulose sodium with preservative	0.5% (solution)	ophthalmic	Strength clarification
carboxymethylcellulose sodium preservative-free (PF)	0.5% minims (solution)	ophthalmic	Strength clarification & restriction update (RS-11)
carboxymethylcellulose sodium PF	1% minims (solution)	ophthalmic	Strength clarification & restriction update (RS-11)
opium & belladonna	65 mg / 15 mg (suppositories)	rectal	Removed from Formulary – product discontinued

### Other Formulary Updates

- **Formulary Policies and Procedures**

- [Compounding Policy](#)

- Calgary Zone LTC Compounding Policy is being revised. The new process will be tested for 6 months. The pilot form will be distributed to contracted pharmacy providers by email.

- [Wardstock/Statbox Lists](#)

- the carboxymethylcellulose sodium 1% PF minims listing was updated.

- **Formulary Medication Listing**

- The [Full Formulary Listing](#) was updated to reflect the changes in the above table.

- **Automatic Substitutions**

- The [Automatic Substitution List-01](#) (ASL-01) was updated:
    - Clarification of strengths for ophthalmic lubricants.

- **Restricted Use Medications**

- The [Restricted Use Medications – Miscellaneous Drugs](#) (RS-11) table was updated:
    - Correction to Brand example for clarithromycin
    - Updated restrictions to carboxymethylcellulose sodium 0.5% and 1% PF minims

**Formulary Changes (Additions, Changes, Deletions)**

The following drug product(s) listing changes to the Calgary Zone Long Term Care Formulary are complete. When available, consider the lowest cost alternative (LCA) product the benefit.

<b>Product Description</b>	<b>Strength (Dosage Form)</b>	<b>Route of Administration</b>	<b>Listing / Comments</b>
apixaban	2.5 mg & 5 mg (tablets)	oral	Removed from Direct oral anticoagulants (RS-48) to full formulary listing (unrestricted)
azithromycin	500 mg (tablet)	oral	Delisted / discontinued by manufacturer
azithromycin	600 mg (tablet)	oral	Delisted due to low utilization, cost
azithromycin	250 mg (tablet)	oral	Removed from Macrolides RS-30 and added to Misc. RS-11. Macrolides RS-30 rescinded.
clarithromycin	250 mg and 500 mg (tablet)	oral	Therapeutic substitution of clarithromycin to azithromycin removed (ASL-01)
dabigatran	75 mg, 110 mg, 150 mg (capsule)	oral	Moved to Misc. (RS-11)
edoxaban	15 mg, 30 mg, and 60 mg (tablet)	oral	Added with restrictions to Misc. RS-11.
erythromycin	333 mg EC (capsule) 250 mg base (tablet)	oral	Delisted / discontinued by manufacturer. Therapeutic substitution from base to EC removed (ASL-01)
linagliptin	5 mg (tablet)	oral	Added as a Special Authorization listing (SA-30)
pseudoephedrine	30 mg (tablet)	oral	Delisted / discontinued by manufacturer

rivaroxaban	10 mg, 15 mg, and 20 mg (tablet)	oral	Moved to Misc. (RS-11)
sitagliptin	25 mg, 50 mg, and 100 mg (tablet)	oral	Added as a Special Authorization listing (SA-30)

### Other Formulary Updates

- **Formulary Medication Listing**
  - The **Full Formulary Listing** was updated to reflect the changes in the above table and pack sizes for many injectables.
  
- **Automatic Substitutions**
  - The **Automatic Substitution List-01** was updated:
    - Removed substitution for oral erythromycin base 250 mg to erythromycin EC 333 mg due to market discontinuation of both.
    - Removed substitution for oral clarithromycin to oral azithromycin due to restriction changes.
  
- **High Cost / Special Authorization**
  - The **DPP-4 inhibitors** - sitagliptin and linagliptin - were added to the Special Authorization form and supplementary document for **SGLT-2 inhibitors SA-30**. Please review the supplement posted on the Formulary website for updated criteria.
    - The updated form will be distributed by email to the pharmacy providers.
  - **Aripiprazole and Brexpiprazole (SA-25)** criteria were updated. The form now includes a protocol for Behavioural and Psychological Symptoms of Dementia. Please review the updated form posted on the website.
  
- **Restricted Use Medications**
  - **Oral Fluoroquinolones (ciprofloxacin, norfloxacin, levofloxacin) (RS-02)** was updated to reflect safety considerations, new protocols for use, restrictions on duration of therapy, and a review and documentation process.
  - **Macrolides (RS-30)** rescinded. Azithromycin and clarithromycin restrictions moved to Miscellaneous Drugs (RS-11)

- **Direct oral anticoagulants (RS-48)** rescinded. Apixaban moved to unrestricted full listing. Rivaroxaban and dabigatran moved to Miscellaneous Drugs (RS-11).
  - Restricted Use **Miscellaneous Drugs (RS-11)** was updated to include new restrictions for azithromycin, clarithromycin, rivaroxaban, edoxaban, and dabigatran.
- **Education**
    - Under **Miscellaneous: “Medication storage of select eye, ear and injectable medications in Long Term Care”** practice support tool added. This is an optional reference tool can be used to support dating and storage of medications at the facility level once medications are on-site.

June 30, 2023

### Formulary Changes (Additions, Changes, Deletions)

The following drug product(s) listing changes to the Calgary Zone Long Term Care Formulary are complete. When available, consider the lowest cost alternative (LCA) product the benefit.

Product Description	Strength (Dosage Form)	Route of Administration	Listing / Comments
budesonide / glycopyrronium bromide / formoterol fumarate dihydrate (Breztri™ Aerosphere®)	182 mcg/dose * 8.2 mcg/dose * 5.8 mcg/dose (inhalation metered dose aerosol)	inhaled	added to Formulary with Restrictions (see RS-11)
dexamethasone	10 mg/mL (10 mL size)	injection	adding 10 mL size for patient-specific dispensing (1 mL size can be used for Statbox or short-course)

### Other Formulary Updates

- **Formulary Medication Listing**
  - The **Full Formulary Listing** was updated to reflect the changes in the above table and pack sizes for many injectables.

- **Restricted Use Medications**

- Restricted Use **Miscellaneous Drugs (RS-11)** was updated to reflect the following:
  - Addition of budesonide 182 mcg/dose / glycopyrronium bromide 8.2 mcg/dose / formoterol fumarate dihydrate 5.8 mcg/dose (Breztri™ Aerosphere®) “For chronic maintenance therapy of COPD under the following conditions:
    1. Add-on therapy for inadequate response to optimal dual-inhaled therapy for COPD. \*Dual-inhaled therapy can be any combination of a long-acting muscarinic antagonist (LAMA), long-acting beta-2 agonist (LABA) or an inhaled corticosteroid (ICS), OR
    2. Current use of triple therapy – LAMA, LABA and ICS -- (including use of multiple inhaler devices), AND clinical assessment indicates that all three drug classes continue to be necessary, AND provided triple therapy was not started as initial therapy.

Ongoing need for triple therapy should be assessed at a minimum annually. The Clinical pharmacist is required to complete the Inhaler Medication Assessment Tool as directed.”

April 30, 2023

---

### Formulary Changes (Additions, Changes, Deletions)

The following drug product(s) listing changes to the Calgary Zone Long Term Care Formulary are complete. When available, consider the lowest cost alternative (LCA) product the benefit.

<b>Product Description</b>	<b>Strength (Dosage Form)</b>	<b>Route of Administration</b>	<b>Listing / Comments</b>
Blephemide (prednisolone / sulfacetamide)	0.2% * 10% (eye drops and eye ointment)	Ophthalmic	Delisted / discontinued by manufacturer
Ceclor (Cefaclor)	250 mg & 500 mg (capsules)	Oral	Removed therapeutic substitution to cefuroxime. Discontinued by manufacturer
Polysporin® Eye Ointment	10 000 unit/g * 500 unit/g (eye ointment)	Ophthalmic	Discontinued by manufacture



(Polymyxin B / bacitracin)			
Pred Mild® Prednisolone	0.12% (solution)	Ophthalmic	Delisted / discontinued by manufacturer
Sterisporin® Eye Ointment (Polymyxin B / bacitracin)	10 000 unit/g * 500 unit/g (eye ointment)	Ophthalmic	Added this brand
Viroptic® (trifluridine)	1% (solution)	Ophthalmic	Delisted / discontinued by manufacturer

### Other Formulary Updates

- **Wardstock updates**

- Add nicotine 2 mg lozenge to Wardstock – Optional

- **Statbox updates**

#### Changes to High Alert Statbox items

- Add insulin aspart 100 units/mL (Trurapi®) **or** insulin lispro 100 units/mL (Admelog®) to Statbox – Optional. Clinical pharmacists to work with sites to determine which rapid-acting insulin is most appropriate based on utilization and prescribing patterns of local physicians. This change would require removal of insulin regular (Humulin R®), which is a Short-acting insulin. Note: these additions/removals would need to be reviewed at site-level for High Alert awareness.
- Add insulin glargine 100 units/mL (Basaglar®) to Statbox – Optional. This change would require removal of insulin NPH (Humulin N®) which is an intermediate acting. Note: these additions/removals would need to be reviewed at site-level for High Alert awareness.
- Add apixaban 2.5 mg tablets to Statbox - Required. Note: this addition would need to be reviewed at site-level for High Alert awareness.
- remove warfarin 3 mg and 5mg tablets from Statbox. Other doses are still available (1mg, 2mg, 2.5mg as required Statbox and 0.25mg and 0.5 mg as optional). Note: these removals would need to be reviewed at site-level for High Alert awareness.

- If not already considered, Tinzaparin 4500 unit/syringe is optional to carry in the Statbox. Note: these additions would need to be reviewed at site-level for High Alert awareness.

#### Other changes to Statbox

- Add amoxicillin 875 mg / clavulanic acid 125 mg tablets to Statbox – Required. (Previously optional)
  - Add cefixime 400 mg tablets to Statbox – Required.
  - Add cefuroxime 250 mg tablets to Statbox – Required. (Previously optional)
  - Add ceftriaxone 1 gm/vial to Statbox – Optional. Limit 1 per main Statbox. (Previously COVID-19 optional)
  - Add dexamethasone 4 mg tablets to Statbox – Optional. (Previously COVID-19 optional)
  - Add dexamethasone 10 mg/mL injection (1 mL size) to Statbox – Optional. (Previously COVID-19 optional)
  - Add lidocaine 1% injection (5 mL size) to Statbox – Optional. (Previously COVID-19 optional)
  - Remove cyanocobalamin 1000 mcg/mL injection (10 mL vial) from Statbox.
  - Remove methotrimeprazine 25 mg/mL injection from Statbox.
  - Remove nicotine 2 mg gum from Statbox (lozenges will be stocked – see Wardstock).
  - Remove nicotine 2 mg lozenge (see Wardstock changes)
  - Remove norfloxacin 400 mg tablets from Statbox.
- **Formulary Medication Listing**
    - The **Full Formulary Listing** was updated to reflect the changes in the above table and pack sizes for many injectables.
  - **Automatic Substitutions**
    - The **Automatic Substitution List-01** was updated:
      - Removed substitution for cefaclor (Ceclor®) to cefuroxime (Ceftin®) since cefaclor is no longer available on the market.
  - **High Cost / Special Authorization**
    - No changes this update
  - **Restricted Use Medications**

- Restricted Use criteria for **cefuroxime (RS-06)** is rescinded. Cefuroxime is now a full formulary listing.
- Restricted Use **Miscellaneous Drugs (RS-11)** was updated to reflect the following:
  - Cyanocobalamin 1000 mcg/mL restriction was added to dispense as patient-specific using 1 mL size.
  - Glucagon rDNA listing now includes either GlucaGen® Hypokit® or Glucagon kit.
- Update to **nebulized medication (RS-21)** with removal of spacer instructions and addition of reference links.